XCSFDHG46767FHJHJF
tdp2664 China Analyst Below are the top 10 Micro Cap stocks with highest upside potential, based on the difference between current price and Wall Street analysts' average target price. One Chinese company (CIS) is on the list. YRC Worldwide Inc. (NASDAQ:YRCW) has the 1st highest upside potential in this segment of the market. Its upside is 873.5%. Its consensus target price is $0.55 based on the average of all estimates. Neostem Inc. (AMEX:NBS) has the 2nd highest upside potential in this segment of the market. Its upside is 480.3%. Its consensus target price is $3.56 based on the average of all estimates. Anooraq Resources Corporation (USA) (AMEX:ANO) has the 3rd highest upside potential in this segment of the market. Its upside is 453.7%. Its consensus target price is $2.99 based on the average of all estimates. NuPathe Inc (NASDAQ:PATH) has the 4th highest upside potential in this segment of the market. Its upside is 449.5%. Its consensus target price is $12.58 based on the average of all estimates. The PMI Group, Inc. (NYSE:PMI) has the 5th highest upside potential in this segment of the market. Its upside is 387.6%. Its consensus target price is $1.50 based on the average of all estimates. Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has the 6th highest upside potential in this segment of the market. Its upside is 372.0%. Its consensus target price is $6.75 based on the average of all estimates. Camelot Information Systems Inc (ADR) (NYSE:CIS) has the 7th highest upside potential in this segment of the market. Its upside is 348.8%. Its consensus target price is $14.36 based on the average of all estimates. Cytokinetics, Inc. (NASDAQ:CYTK) has the 8th highest upside potential in this segment of the market. Its upside is 346.4%. Its consensus target price is $5.00 based on the average of all estimates. Zalicus, Inc. (NASDAQ:ZLCS) has the 9th highest upside potential in this segment of the market. Its upside is 315.8%. Its consensus target price is $4.20 based on the average of all estimates. AVI BioPharma, Inc. (NASDAQ:AVII) has the 10th highest upside potential in this segment of the market. Its upside is 293.9%. Its consensus target price is $3.67 based on the average of all estimates.
No comments:
Post a Comment